Guillaume Connan

Chief Executive Officer at

Helse SAS

Health Technology

Commercial Services

Finance

Profile

Guillaume Connan is currently the Chairman at Chabé Limousines SAS, Chairman at Connan Bonvallet Conseil, Director at Galien Développement SA, and Managing Director at Helse SAS since 2012.
He previously worked as Chairman at Xeltis AG, Director at Nautilus Biotech SA, Director-Investments at Matignon Investissement et Gestion SAS from 2000 to 2010, and Director at Kaneka Eurogentec SA. He also briefly served as Director at QIAGEN Marseille SA in 2010.
Mr. Connan received his undergraduate degree and MBA from École des Hautes Études Commerciales de Paris.

Guillaume Connan active positions

Companies	Position	Start
Helse SAS Helse SAS Investment ManagersFinance Acts as an alternative investment manager	Chief Executive Officer	08/05/2011
Chabé Limousines SAS Chabé Limousines SAS Other TransportationTransportation Provides private chauffeur services	Chairman	-
Connan Bonvallet Conseil Connan Bonvallet Conseil Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services	Chairman	-

All active positions of Guillaume Connan

Former positions of Guillaume Connan

Companies	Position	End
Nautilus Biotech SA Nautilus Biotech SA Pharmaceuticals: MajorHealth Technology Develops and markets innovative biotechnology products	Director/Board Member	09/03/2010
Matignon Investissement et Gestion SAS Matignon Investissement et Gestion SAS Investment ManagersFinance MIG is an active private equity investment manager with a long-term outlook. Originally investing across a variety of industries, the firm has progressively focused on sectors including medical technology, healthcare-related services and biotechnology. They also invest in the information and communication technology sector, and their expansion financing and LBO activities are not sector-specific. MIG acquires significant minority stakes in French, European and US companies, balancing their investments across development stages. The firm targets companies based on a coherent commercial strategy and whose research efforts are mature. They seek board representation. Their exit strategies favor trade sales to large biomedical groups. MIG's specific interests within their sectors of expertise have included orthopedic implants for spinal surgery, nutritional counseling, biodegradable cardiovascular stents, surgical navigation systems, glucose measurement, sleep apnea and HIV non-progression.	Private Equity Investor	20/01/2010
Xeltis AG Xeltis AG Medical SpecialtiesHealth Technology Develops medical devices for heart valve replacement and vascular surgery	Chairman	-
Galien Développement SA Galien Développement SA Miscellaneous Commercial ServicesCommercial Services Provides management and financial services to pharmacies	Director/Board Member	-
Kaneka Eurogentec SA Kaneka Eurogentec SA BiotechnologyHealth Technology Distributes reagents, kits, and other related products for the biotechnology, pharmaceutical, and diagnostic sectors	Director/Board Member	-

See the detail of Guillaume Connan's experience

Training of Guillaume Connan

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Guillaume Connan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	10
Nautilus Biotech SA Nautilus Biotech SA Pharmaceuticals: MajorHealth Technology Develops and markets innovative biotechnology products	Health Technology
Matignon Investissement et Gestion SAS Matignon Investissement et Gestion SAS Investment ManagersFinance MIG is an active private equity investment manager with a long-term outlook. Originally investing across a variety of industries, the firm has progressively focused on sectors including medical technology, healthcare-related services and biotechnology. They also invest in the information and communication technology sector, and their expansion financing and LBO activities are not sector-specific. MIG acquires significant minority stakes in French, European and US companies, balancing their investments across development stages. The firm targets companies based on a coherent commercial strategy and whose research efforts are mature. They seek board representation. Their exit strategies favor trade sales to large biomedical groups. MIG's specific interests within their sectors of expertise have included orthopedic implants for spinal surgery, nutritional counseling, biodegradable cardiovascular stents, surgical navigation systems, glucose measurement, sleep apnea and HIV non-progression.	Finance
Kaneka Eurogentec SA Kaneka Eurogentec SA BiotechnologyHealth Technology Distributes reagents, kits, and other related products for the biotechnology, pharmaceutical, and diagnostic sectors	Health Technology
École des Hautes Études Commerciales de Paris École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
QIAGEN Marseille SA QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services Develops and markets molecular diagnostic tests for cancer	Commercial Services
Chabé Limousines SAS Chabé Limousines SAS Other TransportationTransportation Provides private chauffeur services	Transportation
Galien Développement SA Galien Développement SA Miscellaneous Commercial ServicesCommercial Services Provides management and financial services to pharmacies	Commercial Services
Helse SAS Helse SAS Investment ManagersFinance Acts as an alternative investment manager	Finance
Xeltis AG Xeltis AG Medical SpecialtiesHealth Technology Develops medical devices for heart valve replacement and vascular surgery	Health Technology
Connan Bonvallet Conseil Connan Bonvallet Conseil Miscellaneous Commercial ServicesCommercial Services Provides business and management consulting services	Commercial Services